Serotonin-Dopamine Interaction: Experimental Evidence and Therapeutic Relevance

Prof. Giuseppe Di Giovanni received his Ph.D. in Neuroscience from the University of Chieti, Italy and was a postdoctoral fellow at Yale University, USA. Previously Senior Lecturer of Human Physiology at the Faculty of Medicine and Surgery, University of Palermo, and Associate Professor at the University of Malta, from 2013 he is Professor of Human Physiology at the Medical School of the University of Malta and from 2018 Honorary Professor at Cardiff University, UK. His research focuses on understanding the pathophysiology of monoaminergic systems using electrophysiological and neurochemical approach. He has published more than 120 peer-reviewed papers, edited 7 books and 6 special issues of various journals.

• 1. SEROTONIN-DOPAMINE INTERACTIONS IN THE CENTRAL NERVOUS SYSTEM1. Serotonin-Dopamine Interaction: an overview.2. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies.3. Serotonin-Dopamine Interaction: electrophysiological evidence.4. Functional genetic polymorphisms in serotonin and dopamine gene systems and their significance in behavioural disorders.2. SEROTONIN-DOPAMINE INTERACTIONS IN SCHIZOPHRENIA5. Distribution of 5-HT and DA receptors in primate prefrontal cortex: implications for pathophysiology and treatment.6. Alterations of dopamine and serotonin transmission in schizophrenia.7. Serotonin and dopamine interactions in psychosis prevention.8. Role of serotonin and dopamine receptor binding in antipsychotic efficacy.9. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.10. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.11. Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders.3. SEROTONIN-DOPAMINE INTERACTIONS IN DEPRESSION12. The dorsal raphe nucleus and serotonin —implications for neuroplasticity linked to major depression and Alzheimer’s disease.13. Dynamics of the dopaminergic system as a key component to the understanding of depression.14. Physiological and therapeutic relevance of constitutive activity of 5-HT2A and 5-HT2C receptors for the treatment of depression.15. The role of dopamine and serotonin in suicidal behaviour and aggression.4. SEROTONIN-DOPAMINE INTERACTIONS IN DRUG ADDICTION16. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse. 17. Pharmacological inhibition of dopamine- and serotonin activity blocks spontaneous and cocaine-activated behaviour.18. Serotonin receptors as potential targets for modulation of nicotine use and dependence.19. Dopamine/Serotonin releasers as medications for stimulant addictions.20. PTEN-5-HT2C coupling: A new target for treating drug addiction.5. SEROTONIN-DOPAMINE INTERACTIONS IN MOTOR DISORDERS21. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson’s disease and other motor disorders. 22. Serotonin-Dopamine interaction in the induction and maintenance of LDOPA-induced dyskinesias.23. Parkinson’s disease – opportunities for novel therapeutics to reduce the problems of levodopa therapy.24. Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome.6. SEROTONIN-DOPAMINE INTERACTIONS IN ATTENTIONAL PROCESSES, LEARNING AND MEMORY25. Serotonergic and dopaminergic modulation of attentional processes.26. Dopamine-serotonin interactions in attention-deficit/hyperactivity disorder (ADHD).27. Serotonin/dopamine interaction in learning.28. Serotonin-dopamine interaction in memory formation.29. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking.